APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025190 pages

Choose your research edition.

Industry ResearchLong-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Amgen

Mylan

Kashiv BioSciences

Pfizer

Fresenius Kabi

Coherus BioSciences

Sandoz

Italfarmaco SpA

Evive Biotech

Chugai Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Amoytop Biotech

Qilu Pharmaceutical

CSPC Baike Biopharma

SL Pharm

Lunan Pharmaceutical

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Lenograstim

Pegfilgrastim

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Hospital and Clinic

Pharmacy

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 3. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges Table 4. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers Table 9. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application Table 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lenograstim Table 17. Major Manufacturers of Pegfilgrastim Table 18. Major Manufacturers of Other Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026) Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027-2032) Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (K Units) Table 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (K Units) Table 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026) Table 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital and Clinic Table 30. Major Manufacturers of Pharmacy Table 31. Major Manufacturers of Other Table 32. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 34. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 35. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026) Table 36. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027-2032) Table 37. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (K Units) Table 39. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (K Units) Table 40. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026) Table 41. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027-2032) Table 42. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units) Table 44. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 45. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 49. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 50. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 52. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026) Table 63. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027-2032) Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 68. Amgen Recent Development Table 69. Mylan Company Information Table 70. Mylan Business Overview Table 71. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 73. Mylan Recent Development Table 74. Kashiv BioSciences Company Information Table 75. Kashiv BioSciences Business Overview Table 76. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 78. Kashiv BioSciences Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 83. Pfizer Recent Development Table 84. Fresenius Kabi Company Information Table 85. Fresenius Kabi Business Overview Table 86. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 88. Fresenius Kabi Recent Development Table 89. Coherus BioSciences Company Information Table 90. Coherus BioSciences Business Overview Table 91. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 93. Coherus BioSciences Recent Development Table 94. Sandoz Company Information Table 95. Sandoz Business Overview Table 96. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 98. Sandoz Recent Development Table 99. Italfarmaco SpA Company Information Table 100. Italfarmaco SpA Business Overview Table 101. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 103. Italfarmaco SpA Recent Development Table 104. Evive Biotech Company Information Table 105. Evive Biotech Business Overview Table 106. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 108. Evive Biotech Recent Development Table 109. Chugai Pharmaceutical Company Information Table 110. Chugai Pharmaceutical Business Overview Table 111. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 113. Chugai Pharmaceutical Recent Development Table 114. Jiangsu Hengrui Pharmaceuticals Company Information Table 115. Jiangsu Hengrui Pharmaceuticals Business Overview Table 116. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 118. Jiangsu Hengrui Pharmaceuticals Recent Development Table 119. Amoytop Biotech Company Information Table 120. Amoytop Biotech Business Overview Table 121. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 123. Amoytop Biotech Recent Development Table 124. Qilu Pharmaceutical Company Information Table 125. Qilu Pharmaceutical Business Overview Table 126. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 128. Qilu Pharmaceutical Recent Development Table 129. CSPC Baike Biopharma Company Information Table 130. CSPC Baike Biopharma Business Overview Table 131. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 133. CSPC Baike Biopharma Recent Development Table 134. SL Pharm Company Information Table 135. SL Pharm Business Overview Table 136. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 138. SL Pharm Recent Development Table 139. Lunan Pharmaceutical Company Information Table 140. Lunan Pharmaceutical Business Overview Table 141. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 143. Lunan Pharmaceutical Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 147. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lenograstim Image Figure 9. Pegfilgrastim Image Figure 10. Other Image Figure 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032) Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032) Figure 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032) Figure 26. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 28. U.S. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 33. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 40. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 48. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 59. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Lenograstim
  • Pegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Mylan
  • Kashiv BioSciences
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Sandoz
  • Italfarmaco SpA
  • Evive Biotech
  • Chugai Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • CSPC Baike Biopharma
  • SL Pharm
  • Lunan Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
  1. 2.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Manufacturers
  1. 3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3
4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  1. 4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Type Introduction
  2. 4.1.1 Lenograstim
  3. 4.1.2 Pegfilgrastim
  4. 4.1.3 Other
  5. 4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
  6. 4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  8. 4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032)
  9. 4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type
  10. 4.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  12. 4.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032)
5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  1. 5.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
  6. 5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application
  10. 5.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  12. 5.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032)
6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
  1. 6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
  1. 7.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
  2. 7.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  8. 7.2.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 Kashiv BioSciences
  14. 8.3.1 Kashiv BioSciences Company Information
  15. 8.3.2 Kashiv BioSciences Business Overview
  16. 8.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 8.3.5 Kashiv BioSciences Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Fresenius Kabi
  26. 8.5.1 Fresenius Kabi Company Information
  27. 8.5.2 Fresenius Kabi Business Overview
  28. 8.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 8.5.5 Fresenius Kabi Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Italfarmaco SpA
  44. 8.8.1 Italfarmaco SpA Company Information
  45. 8.8.2 Italfarmaco SpA Business Overview
  46. 8.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 8.8.5 Italfarmaco SpA Recent Developments
  49. 8.9 Evive Biotech
  50. 8.9.1 Evive Biotech Company Information
  51. 8.9.2 Evive Biotech Business Overview
  52. 8.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 8.9.5 Evive Biotech Recent Developments
  55. 8.10 Chugai Pharmaceutical
  56. 8.10.1 Chugai Pharmaceutical Company Information
  57. 8.10.2 Chugai Pharmaceutical Business Overview
  58. 8.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 8.10.5 Chugai Pharmaceutical Recent Developments
  61. 8.11 Jiangsu Hengrui Pharmaceuticals
  62. 8.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 8.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 8.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 8.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 8.12 Amoytop Biotech
  68. 8.12.1 Amoytop Biotech Company Information
  69. 8.12.2 Amoytop Biotech Business Overview
  70. 8.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 8.12.5 Amoytop Biotech Recent Developments
  73. 8.13 Qilu Pharmaceutical
  74. 8.13.1 Qilu Pharmaceutical Company Information
  75. 8.13.2 Qilu Pharmaceutical Business Overview
  76. 8.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 8.13.5 Qilu Pharmaceutical Recent Developments
  79. 8.14 CSPC Baike Biopharma
  80. 8.14.1 CSPC Baike Biopharma Company Information
  81. 8.14.2 CSPC Baike Biopharma Business Overview
  82. 8.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 8.14.5 CSPC Baike Biopharma Recent Developments
  85. 8.15 SL Pharm
  86. 8.15.1 SL Pharm Company Information
  87. 8.15.2 SL Pharm Business Overview
  88. 8.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 8.15.5 SL Pharm Recent Developments
  91. 8.16 Lunan Pharmaceutical
  92. 8.16.1 Lunan Pharmaceutical Company Information
  93. 8.16.2 Lunan Pharmaceutical Business Overview
  94. 8.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 8.16.5 Lunan Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 9.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
  6. 9.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  9. 9.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst